There are 23 females known with Duchenne or Becker muscular dystrophy (DMD or BMD) who have X;autosome translocations that disrupt the X chromosome within band p21. A female with a t(X;4)(p21;q35) translocation was identified prenatally at routine amniocentesis. At birth, she was found to have a raised CK level, consistent with a diagnosis of Duchenne muscular dystrophy. Her cells were fused with mouse RAG cells and the translocated chromosomes were separated from one another and from the normal X chromosome by segregation in the resulting somatic cell hybrids.
Duchenne and Becker muscular dystrophies (DMD and BMD) are X linked muscle wasting disorders caused by mutation in a gene located at Xp21.1 Twenty-three females have been described with DMD and de novo X;autosome translocations with the X chromosome breakpoint at p21 and the autosomal breakpoint variable in location.2 Expression of the disease in these females is the result of nonrandom inactivation of the normal X chromosome and the variable severity of the disease is probably dependent on the percentage of active normal X chromosomes in the muscle fibres. 2 Although all of the translocations break on the X chromosome at p2 1, detailed cytogenetic examination has mapped the translocation exchange points over a large region of Xp21. The DMD gene has been estimated by pulsed field gel analysis to be as large as 2000 kbF7 and has a minimum of 60 exons.8 Southern blot analysis using DMD genomic probes on mousehuman somatic cell hybrids containing one of the two translocation derived chromosomes from several patients has confirmed that the translocation breakpoints are scattered throughout the gene.9 10 Further localisation of translocation breakpoints has been possible with the use of the DMD cDNA clones, 8 11 12 and analysis of four translocation patients has shown breakpoints within large introns, two in intron 1 and two in intron 7.13 To date, all of the published translocation cases were ascertained as females with muscular dystrophy. We have recently had the opportunity to study a t(X;4) translocation first detected in amniotic fluid from a 31 year old undergoing routine prenatal diagnosis. At birth, the child was confirmed to only the structurally normal X chromosome exhibited X inactivation associated folding at Xql2-q21. " This is evidence favouring preferential inactivation of the normal X chromosome in the cultured amniotic fluid cells. Alphafetoprotein and detailed ultrasound examination were normal.
At the time this case was observed, six other females were known to have an X;autosome translocation with an X chromosome breakpoint at p21, and all were ascertained because they had Duchenne or Becker muscular dystrophy. The parents were advised that the fetus was at some increased risk for having malformations and mental retardation because she had a de novo translocation, and for having muscular dystrophy because of the Xp2 1 breakpoint. The absolute risk for muscular dystrophy was uncertain because it was unknown how many phenotypically normal females have a similar translocation. The parents continued the pregnancy. A serum CK assay from the patient at 24 hours of age was 21 450 IU/l. The subsequent assays have ranged from 1260 to 4200 IU/1, grossly raised over the normal range.
At 3 months of age the infant had no dysmorphic features, normal developmental milestones, and a normal neurological examination. Since the age of 3 months she has been examined on two occasions. Although the parents have been hesitant to have muscle biopsies taken, we have been able to obtain blood specimens from her and her parents for lymphoblastoid transformation and molecular analysis.
At 2 1½2 years the patient was talking in short sentences, and was alert and active. The only concern was that she tended to pull herself up from a sitting position on the floor, and although she would walk down stairs, preferred to crawl up stairs. At 41/2 years, her height was 99 cm, weight 18 In order to facilitate molecular analysis of the translocation breakpoint, the translocated chromosomes were separated from each other and from the normal X chromosome in mouse-human hybrids. DNA from hybrid clones was analysed by Southern blot analysis using two X linked polymorphic probes, 754 and 99-6, which flank the DMD locus. The patient was heterozygous for both probes. Clones which contained only the der(X) chromosome, and not the der(4) or the unrearranged X chromosome, had only the 16 kb PstI fragment detected by probe 754. Probe 99-6 did not detect any bands in these hybrid clones. Clones with both the der(X) and der(4) chromosomes, but not the unrearranged X chromosome, had the 16 kb fragment of probe 754 and the 22 kb fragment of probe 99-6. Following back selection of these clones in 6-thioguanine to select for the loss of the der(X) chromosome, hybrids were identified which carried only the der(4) chromosome and had the 22 kb fragment of probe 99-6, but not the 754 hybridising fragment. Thus, the t(X;4) translocation breakpoint mapped between probes 754 and 99-6. Detailed chromosome analysis was not done to determine which other human chromosomes were present in the hybrids.
'[he breakpoint was mapped in the DMD gene by analysis with DMD genomic probes (fig 2) . DNA from the der(X) hybrid contained hybridising fragments with GMGX1 1 (lane 2), while DNA from the der (4) (5) der(X)t(X;4) hybrid, (3) and (6) der (4) (7)father ofpatient, (2) and (8) t(X;4) patient, (3) and (9) mother ofpatient, (4) and (10) der(X)t(X;4) hybrid, (5) and (11) der (4)t(X;4) hybrid, (6) and (12) The CK data and the translocation breakpoint mapping predict that the patient is developing the Duchenne or Becker form of muscular dystrophy. Although milder severity of DMD has been observed in a few of the translocation cases, the severity does not seem to be correlated with the location of the translocation within the DMD gene.9 Any modification in the severity of the disease could be attributed to the potential presence of nuclei with an active normal X chromosome in the muscle fibres.2 When our patient was ascertained, a moderate but undetermined risk for DMD was given to the parents. Should a similar translocation be ascertained today, it would still not be possible to assign an accurate risk, since the proportion of normal females with translocations involving Xp21 is still unknown. However, with the current availability of DMD probes, and the powerful technique of in situ hybridisation, it should be possible to localise probes from opposite ends of the gene on the derivative chromosomes. Should such probes localise on alternate translocation derived chromosomes, it would then be reasonable to conclude that the gene was disrupted by the translocation and assign a high risk figure for DMD.
In a study on the position of nine translocations within the DMD gene using genomic probes, there was no apparent clustering of breakpoints, although there were more in the distal half (3' end) of the gene than the proximal half (5' end). Two Ultimately, we would like to understand the mechanism by which translocation occurs, and an analysis of sequences at or near translocation breakpoints may provide clues. The presence of a repetitive element such as an Alu repeat or a LINE repeat might suggest a homologous exchange between these elements on non-homologous chromosomes. Another possibility is a recognition sequence for an enzyme involved in the translocation process. The CGGC tetranucleotide found in the immediate vicinity of a t(X;21)(p21;pl2) translocation might be a candidate for such a recognition sequence.39 Alternatively, variation in chromatin configuration might lead to an increased probability of rearrangement, a possibility that is supported by the fact that some DMD translocation breakpoints involve autosomal regions coincident with known fragile sites.2 In addition, it is possible that translocation might be the result of a breakage event at a replication fork associated with a nuclear matrix anchorage site, which is repaired by reunion to a replication fork of another chromosome at a nearby anchorage point. This type of mechanism has been postulated in the generation of deletions in the P3 globin gene. 
